Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys (TIGRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00321113
Recruitment Status : Completed
First Posted : May 3, 2006
Last Update Posted : February 24, 2017
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to explore the safety and efficacy of two different immunosuppressive regimens (sequential tacrolimus/mycophenolate mofetil [MMF] plus steroids versus tacrolimus plus MMF, following induction with daclizumab) in recipients of marginal donor kidneys.

Condition or disease Intervention/treatment Phase
KIDNEY TRANSPLANTATION Drug: tacrolimus Drug: mycophenolate mofetil Drug: steroids Phase 3

Detailed Description:

An open, multicentre, randomized, parallel group study to compare in marginal old-for-old renal transplant patients the safety and efficacy of two treatments: sequential mycophenolate mofetil/delayed tacrolimus plus steroids vs tacrolimus plus mycophenolate mofetil, in patients requiring induction with anti-IL2 monoclonal antibody.

Elderly (≥50 years) low risk patients (PRA grade ≤50%, in the previous 6 months) receiving an allograft transplantation of marginal kidney(s) from elderly (>65 years) donors (old-for-old allocation) will be randomized to one of the following treatment arms:

Arm1: Sequential mycophenolate mofetil/tacrolimus/steroids

Arm2: Tacrolimus/mycophenolate mofetil/steroid one single dose (perioperatively)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Multicentre, Randomised, Parallel Group Study to Compare in Marginal Old-for-old Renal Transplant Patients the Safety and Efficacy of Two Treatments: Sequential Mycophenolate Mofetil/Delayed Tacrolimus Plus Steroids vs Tacrolimus Plus Mycophenolate Mofetil in Patients Requiring Induction With Anti-IL2 Antibody
Study Start Date : September 2004
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Drug: tacrolimus
Other Names:
  • Prograf
  • FK506
Drug: mycophenolate mofetil
Other Name: MMF
Experimental: 2
Drug: tacrolimus
Other Names:
  • Prograf
  • FK506
Drug: mycophenolate mofetil
Other Name: MMF
Drug: steroids

Primary Outcome Measures :
  1. Calculated creatinine clearance [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Acute Rejection, patient survival, graft survival [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients minimum 60 years of age undergoing a cadaveric kidney transplant
  • Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation.
  • Donors older than 60 years
  • Female patients of child bearing age agree to practice effective birth control during the study.
  • Patient has been fully informed and has given written informed consent

Exclusion Criteria:

  • Patient has significant, uncontrolled, concomitant infections and/or severe diarrhoea, vomiting, or active peptic ulcer
  • Patient has previously received or is receiving an organ transplant other than kidney or a kidney retransplant
  • Any pathology or medical condition that can interfere with this protocol study proposal
  • Other exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00321113

Bologna, Italy, 40138
Cagliari, Italy, 09134
Milano, Italy, 30100
Modena, Italy, 41100
Padova, Italy, 35128
Palermo, Italy, 90127
Roma, Italy, 00144
Roma, Italy, 00161
Roma, Italy, 00168
Sassari, Italy, 35128
Siena, Italy, 53100
Treviso, Italy
Udine, Italy
Vicenza, Italy, 36100
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Europe B.V.

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00321113     History of Changes
Other Study ID Numbers: FG-506-02-IT-01
First Posted: May 3, 2006    Key Record Dates
Last Update Posted: February 24, 2017
Last Verified: February 2017

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents